Avadel Pharmaceuticals (AVDL) Scheduled to Post Quarterly Earnings on Tuesday

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 122.64% and a negative net margin of 111.64%. The company had revenue of $41.50 million during the quarter, compared to analysts' expectations of $37.47 million. During the same quarter in the prior year, the business posted ($0.70) earnings per share. The company's revenue for the quarter was up 2666.7% compared to the same quarter last year. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avadel Pharmaceuticals Stock Performance

Shares of NASDAQ:AVDL traded up $0.15 on Tuesday, hitting $15.01. The company's stock had a trading volume of 462,234 shares, compared to its average volume of 1,149,138. Avadel Pharmaceuticals has a 12 month low of $10.25 and a 12 month high of $19.09. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -12.70 and a beta of 1.47. The stock's 50-day moving average is $13.66 and its two-hundred day moving average is $15.22.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AVDL. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a report on Thursday, October 31st. Oppenheimer upped their price objective on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Avadel Pharmaceuticals in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $24.71.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.